{"title":"生物制剂如何适应医疗改革?由于变数太多，很难预测2014年生物制剂和其他特殊药品的市场将会是怎样的。当前的趋势或许能提供一些启示。","authors":"Michael D Dalzell","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The Institute of Medicine says that health benefit packages should be limited by cost, not services, but doesn't address the coverage of biologics. Employers, meanwhile, are thinking about limiting access to high-priced drugs. Yet, industry reports say that biologics are set to dominate drug spend by 2015. Are we moving toward healthcare rationing?</p>","PeriodicalId":89534,"journal":{"name":"Biotechnology healthcare","volume":"8 4","pages":"6-10"},"PeriodicalIF":0.0000,"publicationDate":"2011-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278131/pdf/bh0804006.pdf","citationCount":"0","resultStr":"{\"title\":\"How Will Biologics Fit Into Healthcare Reform?: With so many variables, it's hard to predict what kind of market will exist for biologics and other specialty drugs in 2014. Current trends may provide some insight.\",\"authors\":\"Michael D Dalzell\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The Institute of Medicine says that health benefit packages should be limited by cost, not services, but doesn't address the coverage of biologics. Employers, meanwhile, are thinking about limiting access to high-priced drugs. Yet, industry reports say that biologics are set to dominate drug spend by 2015. Are we moving toward healthcare rationing?</p>\",\"PeriodicalId\":89534,\"journal\":{\"name\":\"Biotechnology healthcare\",\"volume\":\"8 4\",\"pages\":\"6-10\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278131/pdf/bh0804006.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biotechnology healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biotechnology healthcare","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
美国医学研究所(Institute of Medicine)表示，健康福利计划应该受成本限制，而不是服务，但它并没有解决生物制剂的覆盖问题。与此同时，雇主们正在考虑限制获得高价药品的途径。然而，行业报告称，到2015年，生物制剂将主导药品支出。我们正在走向医疗配给吗?
How Will Biologics Fit Into Healthcare Reform?: With so many variables, it's hard to predict what kind of market will exist for biologics and other specialty drugs in 2014. Current trends may provide some insight.
The Institute of Medicine says that health benefit packages should be limited by cost, not services, but doesn't address the coverage of biologics. Employers, meanwhile, are thinking about limiting access to high-priced drugs. Yet, industry reports say that biologics are set to dominate drug spend by 2015. Are we moving toward healthcare rationing?
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
